Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
Prevalence of Genomic Alterations in EGFR, KRAS, NRAS, and BRAF Among Early-Stage Nonsquamous Non-Small Cell Lung Cancer in Brazil.
Marques FK et al.
Jco Global Oncology, 2026
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Genomic profiling of aggressive pathologic features in lung adenocarcinoma.
Lin YD et al.
Lung Cancer (amsterdam, Netherlands), 2025
Analysis of the Relationship Between EGFR Mutations and PD-L1, ALK, and ROS1 Alterations in Patients with Non- Small-Cell Lung Cancer: The Most Extensive Study Conducted in Iran.
Hadimaleki S et al.
Turk Patoloji Dergisi, 2025
The prevalence and clinical significance of EGFR mutations in non-small cell lung cancer patients in Egypt: a screening study.
Helal AA et al.
Journal of the Egyptian National Cancer Institute, 2024
Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-review.
Dempke WCM et al.
Translational Cancer Research, 2024
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report.
Cosi DM et al.
International Journal of Molecular Sciences, 2024
Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.
Slomka J et al.
Plos One, 2024
Non-Small Cell Lung Cancer: Targetable Variants in Concurrent Tissue and Liquid Biopsy Testing in a North Indian Cohort.
Paturu R et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2023
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C et al.
Pharmaceutics, 2023
Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening.
Suda K et al.
Cancers, 2023
Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective.
Ong HW et al.
Acs Chemical Neuroscience, 2023
Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer.
Huang HM et al.
Balkan Journal of Medical Genetics : Bjmg, 2023
All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.
Ullas B et al.
Journal of Cancer Research and Clinical Oncology, 2023
Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer.
Goto K et al.
Cancer Medicine, 2023
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
Takeda M et al.
Lung Cancer (amsterdam, Netherlands), 2023
Frequency of EGFR mutations in lung adenocarcinoma patients - A study from tertiary cancer center of South India.
Nayanar SK et al.
Journal of Cancer Research and Therapeutics, 2023
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing.
Lee J et al.
Journal of Pathology and Translational Medicine, 2022
Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis.
Kitadai R et al.
Cancers, 2022
Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Mambetsariev I et al.
Journal of Clinical Medicine, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Two Unusual Mutations in the Epidermal Growth Factor Receptor Gene in a Patient With Lung Adenocarcinoma.
Zapata Laguado M et al.
Cureus, 2022
Prevalence of targeted therapy-related genetic variations in NSCLC and their relationship with clinicopathological characteristics.
Li F et al.
Plos One, 2022
Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung.
Wang H et al.
Frontiers in Oncology, 2022
Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation.
Ko HW et al.
Frontiers in Immunology, 2022
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Koopman B et al.
Cancers, 2021
Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.
Gilson P et al.
Scientific Reports, 2021
Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418).
Mascarenhas E et al.
Thoracic Cancer, 2021
Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer.
Si X et al.
Thoracic Cancer, 2021
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
de Marinis F et al.
Lung Cancer (amsterdam, Netherlands), 2021
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1.
Park CK et al.
Cancer Research and Treatment, 2021
Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer.
Zhang X et al.
Frontiers in Oncology, 2021
Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.
Zhao S et al.
Biomed Research International, 2021
Analysis of Multigene Mutations in Lung Adenocarcinoma in Zunyi.
Ma Q et al.
Biomed Research International, 2021
Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory.
Mao L et al.
Pathology Oncology Research : Por, 2021
EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes.
Xu H et al.
Frontiers in Oncology, 2021
Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study.
Lin X et al.
Frontiers in Oncology, 2021
EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.
Tarigopula A et al.
Cancer Reports (hoboken, N.j.), 2020
Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay.
Song X et al.
British Journal of Cancer, 2020
Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation.
Lee SH et al.
Cancer Biology & Therapy, 2020
Subtyping and EGFR mutation testing from blocks of cytological materials, based on liquid-based cytology for lung cancer at bronchoscopic examinations.
Tanaka R et al.
Diagnostic Cytopathology, 2020
Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma.
Yamaura T et al.
Oncology Letters, 2020
[Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis].
Hu Y et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2020
[Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].
Liang Y et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2020
Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer.
Lombardi A et al.
High-throughput, 2020